乙肝特异性主动免疫治疗慢性乙型肝炎病毒感染的临床研究  

A Clinical Study on Using Specific Active Immunotherapy in the Treatment of Chronic HBV Infection

作　　者：李旭红[1] 王崇国[1] 杨红[1] 李树青[1] 潘兴南[1] 陈丽娟[1] 缪松毅[1] 

机构地区：[1]中国人民解放军第180医院,福建泉州362000

出　　处：《中西医结合肝病杂志》2001年第S1期21-23,共3页Chinese Journal of Integrated Traditional and Western Medicine on Liver Diseases

摘　　要：目的:探讨乙型肝炎特异性主动免疫疗法治疗慢性乙型肝炎病毒感染的疗效。方法:以乙肝特异性主动免疫疗法为治疗组(639例),抗乙肝免疫核糖核酸为对照组(429例),进行前瞻性、多中心临床研究。采用序贯随机分组方法,对入选的1068例慢性乙型肝炎病毒感染患者进行为期6个月的治疗。结果:乙型特异性主动免疫疗法组中CHB组的HBsAg、HBeAg、HBV DNA阳性及HBV DNA与HBeAg双阳性患者的阴转率分别达5.0％、19.1％与18.3％,明显高于对照组(P<0.01)。结论:乙肝特异性主动免疫疗法可能是治疗慢性乙型肝炎安全有效的治疗方法,值得进一步研究。Objective: To investigate the efficacy of specific active immunotherapy (SAD in the treatment of chronic hepatitis B. Methods: The study was a prospetive multi-center clinical study. 1068 patients with chronic HBV infection were randomly assigned into 2 groups. The first group containing 639 cases were treated with SAIt the second group including 429 cases received anti-HBV immune RNA (Anti-HBV iRNA) treatment. The duration of such two therapy was 6 months. Results: The seronegative rate of HBsAg, HBeAg, HB...

关 键 词：特异性主动免疫疗法 慢性乙型肝炎 临床疗效 

分 类 号：R512.6[医药卫生—内科学]